Trump IVF proposals aim to increase access to fertility treatments

The Trump administration has recently announced a groundbreaking deal with EMD Serono to lower drug prices as part of a larger effort to increase coverage and affordability for fertility services. This deal includes the drugmaker committing to reduce drug prices, implementing new benefits rules to encourage employers to offer in vitro fertilization (IVF) coverage outside of health insurance, and providing a Food and Drug Administration priority review voucher for a fertility drug not currently available in the U.S.

EMD Serono, the U.S. subsidiary of German company Merck, is the third pharmaceutical company to strike a deal with the administration, following Pfizer and AstraZeneca. The company has agreed to offer direct-to-consumer sales of its IVF therapies and participate in the TrumpRx purchasing platform in 2026. Some of the IVF medications manufactured by EMD Serono include Gonal-f, Ovidrel, and Cetrotide. The new program will make these medications available at an 84% discount compared to list prices, with the expectation of cutting IVF treatment costs in half.

The administration’s plan aims to lower drug costs through negotiations with pharmaceutical companies. However, the details of the agreements remain confidential, leading experts to question the potential impact on drug prices for most Americans. Despite this, the deal with EMD Serono is considered unique as it expands access and lowers costs for high-demand fertility treatments.

IVF has become a standard procedure for addressing infertility, affecting one in six individuals globally according to the World Health Organization. The treatment involves stimulating egg production, retrieving eggs, and fertilizing them with sperm in a lab dish. Despite its effectiveness, IVF has remained financially out of reach for many families, with costs ranging from $15,000 to $30,000 per cycle. Insurers have traditionally considered IVF to be medically unnecessary, further adding to the financial burden for individuals seeking treatment.

The deal with EMD Serono also involves pharmacy benefit managers, with CVS Specialty’s fertility pharmacy and Express Scripts Freedom Fertility Pharmacy agreeing to reduce expenses associated with fertility treatments. Employers are increasingly opting to cover fertility treatments, with 21 states mandating private insurance coverage. However, self-insured plans and most state Medicaid programs do not cover IVF services, limiting access for many individuals.

The administration’s focus on lowering drug prices and increasing access to fertility treatments is a step towards addressing the healthcare crisis surrounding IVF in the U.S. By incentivizing employers to offer coverage and reducing drug costs, the hope is to make IVF more accessible and affordable for those in need. The recent changes in coverage rules from the Departments of Labor, Treasury, and HHS have sparked both praise and criticism from various quarters. According to officials, these changes could potentially reduce out-of-pocket expenses for employees, making healthcare more affordable. However, critics argue that the administration’s approach does little to address the fundamental challenges faced by families when it comes to accessing healthcare services.

One of the key aspects of these changes is the call for employers to offer insurance coverage for in vitro fertilization (IVF). While this move has been lauded by some, including President Trump, Senator Elizabeth Warren has criticized it, accusing the administration of making false promises about making IVF accessible to every family for free. The debate around healthcare coverage and accessibility continues to be a contentious issue in the current political landscape.

In a bid to incentivize pharmaceutical companies to lower drug prices, EMD Serono has taken a proactive step by offering a priority voucher from the FDA for its drug Pergoveris. This drug, similar to Gonal-f, aids in stimulating egg production in the ovaries but offers a more streamlined administration process. By expediting the review process for Pergoveris, EMD Serono hopes to not only improve patient experience but also reduce costs associated with IVF treatments.

The FDA’s Commissioner’s National Priority Voucher program, announced earlier this year, aims to fast-track drug reviews for companies that align with the administration’s healthcare priorities. EMD Serono is among the first recipients of this program, signaling a new era of faster drug approvals and potentially more accessible treatments for patients.

While there is no mandatory requirement for employers to offer IVF coverage, President Trump has urged companies to consider including it in their insurance plans. This move is seen as a step towards promoting family planning and reproductive healthcare in the country.

In conclusion, the changes in coverage rules and pharmaceutical incentives introduced by the Trump administration have sparked a mix of reactions. While some see it as a positive step towards making healthcare more affordable and accessible, others remain skeptical about the long-term impact of these policies. As the debate continues, it is crucial to strike a balance between incentivizing innovation in the healthcare sector and ensuring that essential services are accessible to all.